Zydus Lifesciences arm gets USFDA tentative nod for Levomilnacipran capsule

The drug is a generic version of Fetzima capsules. Levomilnacipran is a serotonin and norepinephrine reuptake inhibitor used to treat major depressive disorder in adults

FPJ Web DeskUpdated: Monday, January 16, 2023, 10:19 AM IST
article-image
Zydus Lifesciences arm gets USFDA tentative nod for Levomilnacipran capsule | Image: Zydus Lifesciences Ltd (Representative)

Zydus Lifesciences Ltd's subsidiary, Zydus Pharmaceuticals (USA) Inc, has received tentative approval from the US Food and Drug Administration to market Levomilnacipran extended-release capsules in 20 mg, 40 mg, 80 mg, and 120 mg strengths, the company said in an exchange filing.

The drug is a generic version of Fetzima capsules. Levomilnacipran is a serotonin and norepinephrine reuptake inhibitor used to treat major depressive disorder in adults.

The drug will be manufactured at the group's formulation manufacturing facility at Moraiya, Ahmedabad, India.

According to the research firm IQVIA, levomilnacipran tablets sold $85 million in the United States in the fiscal year ended September.

The group now has 341 approvals and has so far filed over 431 abbreviated new drug applications since the commencement of the filing process in 2003-04 (Apr-Mar).

(If you have a story in and around Mumbai, you have our ears, be a citizen journalist and send us your story here. )

(To receive our E-paper on WhatsApp daily, please click here.  To receive it on Telegram, please click here. We permit sharing of the paper's PDF on WhatsApp and other social media platforms.)

RECENT STORIES

Earnings 2023 LIVE: Indigo net profit jumps to Rs 1,422.61 cr; Paytm's losses narrow down to Rs...

Earnings 2023 LIVE: Indigo net profit jumps to Rs 1,422.61 cr; Paytm's losses narrow down to Rs...

Tech layoffs: Apple CEO Tim Cook says job cuts will be last resort

Tech layoffs: Apple CEO Tim Cook says job cuts will be last resort

Vodafone-Idea AGR saga: A breakdown of dues and a complete timeline of the case

Vodafone-Idea AGR saga: A breakdown of dues and a complete timeline of the case

Government rescues Vodafone Idea, converts dues into 35% stake

Government rescues Vodafone Idea, converts dues into 35% stake

Another blow for Indian pharma, drug linked to vision loss in US recalled

Another blow for Indian pharma, drug linked to vision loss in US recalled